Clinical trial
S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary…
NCT00002849 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00002849 |
|---|---|
| Title | S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis |
| Official title | Phase II Study of Dexamethasone/Alpha-Interferon in AL Amyloidosis |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH Cancer and Leukemia Group B |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Biological, Drug |
| Interventions | recombinant interferon alfa, dexamethasone |
| Enrollment | 93 |
| Start date | Nov 1, 1996 |
| Primary completion | Dec 1, 1998 |
| Completion | Jul 1, 2000 |
| First posted | Jan 27, 2003 |
| Last update posted | Mar 6, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: